Sign in or Join FriendFeed
FriendFeed is the easiest way to share online. Learn more »
Sally Church

Sally Church

Interested in Pharma, Biotech, Science and cancer... Find me at http://www.pharmastrategyblog.com also love food, wine, the NFL and cricket. Hi!
Future Medicine - Personalized Medicine - 6(6):681 - Summary - http://www.futuremedicine.com/doi...
Where do members of the public turn to understand what genetic tests mean in terms of their own health? Now that genome-wide association studies and complete genome sequencing are widely available, the importance of education in personalized genomics cannot be overstated. Although some media have introduced the concept of genetic testing to better understand health and disease, the public’s understanding of the scope and impact of genetic variation has not kept up with the pace of the science or technology. - Sally Church
Amgen's Vectibix is dead in colorectal cancer - http://www.pharmastrategyblog.com/2009...
Continuous learning in Pharma marketing - http://www.pharmastrategyblog.com/2009...
Courier: First Details of Microsoft's Secret Tablet - Microsoft courier tablet - Gizmodo - http://gizmodo.com/5365299...
Courier is a real device, and we've heard that it's in the "late prototype" stage of development. It's not a tablet, it's a booklet. The dual 7-inch (or so) screens are multitouch, and designed for writing, flicking and drawing with a stylus, in addition to fingers. They're connected by a hinge that holds a single iPhone-esque home button. Statuses, like wireless signal and battery life, are displayed along the rim of one of the screens. On the back cover is a camera, and it might charge through an inductive pad, like the Palm Touchstone charging dock for Pre. - Sally Church
Consciousness and awareness in Pharma marketing - http://www.pharmastrategyblog.com/2009...
Does the US have the best healthcare system in the world? - http://www.pharmastrategyblog.com/2009...
A Conversation With Brian J. Druker, M.D. - Researcher Behind the Drug Gleevec - Interview - NYTimes.com - http://www.pharmastrategyblog.com/2009...
ATLAS Trial Falls Short of Overall Survival Benefit - http://cancergrace.org/lung...
PTEN dosage is essential for neurofibroma development and malignant transformation — PNAS - http://www.pnas.org/content...
Patients with neurofibromatosis type 1 (NF1) carry approximately a 10% lifetime risk of developing a malignant peripheral nerve sheath tumor (MPNST). Although the molecular mechanisms underlying NF1 to MPNST malignant transformation remain unclear, alterations of both the RAS/RAF/MAPK and PI3K/AKT/mTOR signaling pathways have been implicated. - Sally Church
AstraZeneca withdraws Zactima from EMEA and FDA in lung cancer - http://www.pharmastrategyblog.com/2009...
Using video in social media to bring science and biotechnology alive - http://www.pharmastrategyblog.com/2009...
Medivation and Astellas ink deal for MDV3100 in prostate cancer - http://www.pharmastrategyblog.com/2009...
New MicroRNA Data Could Classify Bladder Cancer By Type - http://www.pharmastrategyblog.com/2009...
Google Docs Batch Export - http://googlesystem.blogspot.com/2009...
Now you can export all your documents, spreadsheets, presentations and PDFs from Google Docs in a ZIP archive. - Sally Church
Now you can export all your documents, spreadsheets, presentations and PDFs from Google Docs in a ZIP archive. - Sally Church
A leap of faith - AB Science and masitinib in pancreatic cancer - http://www.pharmastrategyblog.com/2009...
Pfizer Launches Phase 3 Clinical Trial With Novel Alk Inhibitor In Non-Small Cell Lung Cancer Patients With Specific Gene Mutation - http://mediaroom.pfizer.com/portal...
The overall response rate, to date, is 65 percent (20/31 patients [95 percent CI: 45 percent, 81 percent]) and disease control rate (DCR) at 8 weeks is 84 percent (26/31 patients [95 percent CI: 66 percent, 95 percent]). Median PFS has not yet been reached. The median duration of treatment is 24.5+ weeks. - Sally Church
The FINANCIAL - Pfizer Launches Phase 3 Clinical Trial With Novel Alk Inhibitor In NSCLC Patients With Specific Gene - http://www.finchannel.com/news_fl...
PF-02341066 is an investigational, selective, ATP-competitive small molecule dual inhibitor of mesenchymal epithelial transition growth factor (c-Met or hepatocyte growth factor) and ALK tyrosine kinases, which are implicated in the progression of several cancers, including NSCLC. A subset of NSCLC patients have been identified whose tumors carry a unique mutation in which the echinoderm microtubule-associated protein-like 4 (EML4) gene is fused to ALK, also known as an EML4-ALK translocation. - Sally Church
The real heroes of the Pharma industry are the patients - http://www.pharmastrategyblog.com/2009...
Dove Medical Press - Open Access Papers - http://www.dovepress.com/imatini...
Dermatofibrosarcoma protuberans (DFSP) is a soft tissue tumor with tendency to recur locally and only rarely metastasizes to vital organs. Surgery with wide margins remains the standard treatment. DFSP is characterized by specific chromosomal abnormalities involving the platelet derived growth factor B locus (PDGFB). - Sally Church
Other ways to read this feed:Feed readerFacebook